NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) EPS for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.08. During the same period last year, the company posted ($0.24) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Spectrum Pharmaceuticals.

5 brokers have issued twelve-month price targets for Spectrum Pharmaceuticals' shares. Their forecasts range from $4.00 to $21.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $13.20 in the next twelve months. This suggests a possible upside of 307.4% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

News coverage about SPPI stock has been trending very positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spectrum Pharmaceuticals earned a news sentiment score of 3.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 11,460,000 shares, an increase of 31.9% from the December 15th total of 8,690,000 shares. Based on an average trading volume of 1,980,000 shares, the short-interest ratio is presently 5.8 days. Approximately 11.7% of the company's stock are sold short. View Spectrum Pharmaceuticals' Current Options Chain.

Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Zynerba Pharmaceuticals (ZYNE), TG Therapeutics (TGTX), Amicus Therapeutics (FOLD), Verastem (VSTM), Bausch Health Companies (BHC) and AT&T (T).

Spectrum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Alpine Global Management LLC (0.15%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

SPPI stock was purchased by a variety of institutional investors in the last quarter, including Alpine Global Management LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SPPI stock can currently be purchased for approximately $3.24.

Spectrum Pharmaceuticals has a market capitalization of $366.02 million and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.View Additional Information About Spectrum Pharmaceuticals.

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]